Gilead's Livdelzi Shows Promising Results in Liver Disease Study
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome
Image: Benzinga
Gilead Sciences, Inc. announced positive results from the Phase 3 IDEAL study, demonstrating that Livdelzi (seladelpar) significantly improved alkaline phosphatase (ALP) normalization in patients with primary biliary cholangitis (PBC). The findings support treatment in an underrepresented patient population with inadequately controlled disease.
- 01The Phase 3 IDEAL study showed that Livdelzi led to a significant increase in normalization of ALP levels in patients with primary biliary cholangitis (PBC) after 52 weeks.
- 02The study focused on patients inadequately controlled by ursodeoxycholic acid (UDCA), a group often overlooked in clinical trials.
- 03Cynthia Levy, a hepatology expert, highlighted that the results support ALP normalization as a key therapeutic goal for PBC patients.
- 04Gilead plans to present full IDEAL study data at a medical congress and engage with regulatory authorities regarding the findings.
- 05In a post hoc analysis, Livdelzi showed sustained ALP normalization rates, with 83% of participants achieving normalization at 12 months.
Advertisement
In-Article Ad
Gilead Sciences, Inc. has announced promising results from its Phase 3 IDEAL study, which evaluated the efficacy of Livdelzi (seladelpar) in patients with primary biliary cholangitis (PBC). The study revealed that significantly more patients achieved normalization of alkaline phosphatase (ALP), a critical liver disease marker, compared to those receiving a placebo after 52 weeks. The findings are particularly relevant for patients inadequately controlled by ursodeoxycholic acid (UDCA), a demographic often underrepresented in clinical trials. Safety profiles for Livdelzi remained consistent with previous studies, with no new safety concerns identified. Experts, including Cynthia Levy, emphasized that these results broaden the evidence supporting Livdelzi's use and reinforce the importance of ALP normalization as a treatment goal. Gilead plans to present the full data at an upcoming medical congress and engage with global regulatory authorities to discuss the implications of these findings. Additionally, a post hoc analysis indicated high rates of sustained ALP normalization among participants in ongoing studies.
Advertisement
In-Article Ad
The results from the IDEAL study may influence treatment protocols for patients with primary biliary cholangitis (PBC), potentially improving patient outcomes.
Advertisement
In-Article Ad
Reader Poll
What do you think about the results of Gilead's IDEAL study?
Connecting to poll...
Read the original article
Visit the source for the complete story.